Applied and Environmental Microbiology, April 2000, p. 1400-1404, Vol. 66, No. 4
0099-2240/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
,*

Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Machida, Tokyo 194-8533, Japan
Received 4 November 1999/Accepted 18 January 2000
| |
ABSTRACT |
|---|
|
|
|---|
The secondary metabolite 6-demethylchlortetracycline (6-DCT), which is produced by Streptomyces aureofaciens, is used as a precursor of semisynthetic tetracyclines. Strains that produce 6-DCT also produce a melanin-like pigment (MP). The correlation between MP production and 6-DCT production was investigated by using S. aureofaciens NRRL 3203. Production of both MP and 6-DCT was repressed by phosphate or ammonium ions, suggesting that syntheses of these compounds are controlled by the same regulators. Ten chlortetracycline-producing recombinants were derived from 6-DCT-producing mutant NRRL 3203 by gene replacement. All of the recombinants produced chlortetracycline but not MP, indicating that MP production is the results of a defect in the 6-methylation step and suggesting that the polyketide nonaketideamide is a common intermediate leading to MP as well as 6-DCT. To further examine the possibility that MP might be synthesized via the 6-DCT-biosynthetic pathway, mutants defective in 6-DCT biosynthesis were derived from a 6-DCT producer. Some of these mutants were able to produce MP, while others, including mutants with mutations in the gene encoding anhydrotetracycline oxygenase, an enzyme catalyzing the penultimate step in the pathway, produced neither 6-DCT nor MP. Production of 6-DCT and production of MP were restored simultaneously by integrative transformation with the corresponding 6-DCT-biosynthetic genes, indicating that some of 6-DCT-biosynthetic enzymes are indispensable for MP production. These findings suggest that a defect in the 6-methylation step results in redirection of carbon flux from a certain intermediate in the 6-DCT-biosynthetic pathway to a shunt pathway and results in MP production.
| |
INTRODUCTION |
|---|
|
|
|---|
Secondary metabolic pathways of Streptomyces species sometimes allow cells to produce not only one end product but also structurally related compounds (3, 6, 23). The diversity of metabolites is attributed to the low substrate specificity of some of the secondary metabolic enzymes and to chemical instability of some of the intermediates (5). Such a situation is frequently encountered as an accumulation of shunt products instead of intermediates when a step in the secondary metabolic pathway is blocked (15, 20). Some of these shunt products form pigments that are structurally similar to the desired end product of the pathway.
Chlortetracycline (CTC) biosynthesis in Streptomyces aureofaciens has been well investigated (2, 20, 26). A type II polyketide synthase constructs the CTC skeleton, and 11 subsequent reactions modify the CTC skeleton. The final products in the pathway are four tetracycline antibiotics, CTC, tetracycline (TC), 6-demethylchlortetracycline (6-DCT), and 6-demethyltetracycline (6-DMT). TC and 6-DCT are formed when the 7-chlorination step and the 6-methylation step, respectively, in the pathway are blocked, and 6-DMT is formed when both of these steps are blocked. Deficiencies in the other steps of the CTC-biosynthetic pathway result in cells that cannot synthesize these four tetracycline antibiotics.
Mutants of S. aureofaciens that lack the 6-methylation step produce the yellow compound 6-DCT, which is an industrial material used for production of semisynthetic tetracyclines, and simultaneously produce dark brown pigments that accumulate in the media (4, 21). Recently, the dark brown melanin-like pigment (MP) produced in a culture of S. aureofaciens NRRL 3203, an organism that produces 6-DCT, was purified and was shown to have absorption and electron spin resonance spectra similar to those of melanin (12, 25a). However, the parent strain does not contain tyrosinase, suggesting that the pigment is derived from TC-related compounds (18). In this study, we examined the relationship between 6-DCT and MP, and below we discuss the mechanism of MP production in 6-DCT-producing S. aureofaciens strains.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Bacterial strains and plasmids.
S. aureofaciens NRRL
2209 (wild type) was used as the DNA donor for cloning DNA that
complemented the 6-methylase deficiency. Strain H-7591, which was
derived through several rounds of mutagenesis from S. aureofaciens NRRL 3203, was used for mutation analysis. Other
strains which we used are described in Table
1. Escherichia coli JM110
(29), purchased from Funakoshi (Tokyo, Japan), was used as a
host strain for preparation of a cosmid library and for isolation of
dam and dcm plasmid DNAs used for integrative transformation of S. aureofaciens. Cosmid pHC79
(11), purchased from Boehringer Mannheim (Indianapolis,
Ind.), was used for preparation of a cosmid library. Integrative vector
pSE119 was constructed by inserting a 1.1-kb BclI fragment
containing the tsr gene prepared from plasmid pIJ702
(13) into the BglII site of E. coli
plasmid pUC19-Bgl (7).
|
Media and culture condition. SK2 medium and PK2 medium were used during cultivation of Streptomyces strains as the seed and production media, respectively. SK2 medium contained (per liter) 20 g of soluble starch (stabilose K; Matsutani Kagaku Kogyo, Hyogo, Japan), 5 g of glucose, 5 g of yeast extract, 5 g of peptone, 3 g of Ehrlich meat extract, 0.2 g of KH2PO4, and 0.6 g of MgSO4 · 7H2O in deionized water (pH 7.6). PK2 medium contained (per liter) 50 g of corn starch, 60 g of soybean meal, 40 g of soybean oil, 5 g of KCl, 0.05 g of MgSO4 · 7H2O, 0.05 g of CuSO4, 0.05 g of ZnSO4, and 20 g of CaCO3 in deionized water (pH 6.5). To produce tetracyclines and MP, frozen stock mycelium or spores in 20% glycerol were inoculated into a small test tube containing 4 ml of SK2 medium and cultivated aerobically at 28°C to the stationary phase (40 h). A portion (0.5 ml) of the seed culture was transferred to a large test tube containing 10 ml of SK2 medium. After 24 h of cultivation at 28°C, 1 ml of the seed culture was transferred into a 300-ml flask containing 30 ml of PK2 medium. Cultivation was carried out aerobically at 28°C for 6 days.
General DNA techniques. Conventional DNA manipulations were carried out by using standard procedures (19). Labelling of DNA probes, hybridization, and detection were performed by using the DIG system (Boehringer Mannheim). Genomic DNAs were isolated from Streptomyces strains by the method of Hopwood et al. (13). The plasmids used to transform S. aureofaciens were prepared from E. coli JM110 with a Qiagen (Hilden, Germany) plasmid kit.
Genetic complementation by integrative transformation of the S. aureofaciens mutants with wild-type genes was performed by the method of Kormanec et al. (16). The plasmid integrants were identified by plating transformed cells onto RA medium (8) containing 20 µg of thiostrepton per ml. Protoplast preparation and transformation in S. aureofaciens were performed as described by Dairi et al. (8). Generation of gene replacement recombinants by double crossovers from the plasmid integrants was performed by using protoplast formation and regeneration under nonselective culture conditions. Recombinants were selected from the thiostrepton-sensitive segregants by performing a high-performance liquid chromatography (HPLC) analysis of fermentation products, and excision of the integrated DNAs from the chromosome was confirmed by performing a Southern analysis in which the plasmid DNAs were the probes.Isolation of blocked mutants. Vegetative mycelia of S. aureofaciens H-7591 grown in 10 ml of SK2 medium were harvested, resuspended in 30 ml of 50 mM Tris-maleate buffer (pH 6.0) containing N-methyl-N'-nitro-N-nitrosoguanidine (500 µg/ml), and incubated at 30°C for 30 min. The mutagenized mycelia were washed twice with sterile water and spread onto ISP medium 2 (Difco). After incubation at 28°C for 2 weeks, spores were harvested, and appropriate dilutions were spread onto antibiotic medium 4 (Difco). Mutants that did not produce 6-DCT were selected by performing a bioassay with E. coli JM110, followed by an HPLC analysis of the fermentation products.
Analytical methods. Cell growth was monitored by determining the packed-cell volume ratio of the culture broth after centrifugation (1,600 × g, 10 min). The total sugar content was determined by the method of Dubois et al. (10).
Tetracyclines and 6-demethylanhydrochlortetracycline (Cl-DMATC) (8, 28) were assayed by performing an HPLC analysis. The culture broth was acidified with HCl (final concentration, 0.1 M), and 0.3 volumes of n-propanol were added. The sample was shaken vigorously, and the supernatant after centrifugation (1,600 × g, 3 min) was subjected to a reversed-phase HPLC analysis (17) performed with a YMC-Pack ODS-A column (5 µm; 4.6 mm [inside diameter] by 250 mm; YMC, Tokyo, Japan); the mobile phase was CH3CN-0.1 M citrate buffer (20:80, pH 2.0), the flow rate was 1 ml min
1, and A270 was used
to detect compounds.
MP was assayed by the method described by Tomita (25a) as
follows. The culture broth was acidified with 0.1 N HCl to pH 2 to 3. The precipitate was collected by centrifugation (1,600 × g, 10 min) and resuspended in 0.1 N NaOH, and the preparation was
thoroughly mixed. The precipitation-extraction treatment was repeated
three times, and the A475 of the supernatant was
determined. The concentration of MP was determined by determining the
absorption coefficient at 475 nm (E1 cm1% = 247) (25a).
Chemicals. All of the tetracyclines except 6-DMT were purchased from Sigma-Aldrich (St. Louis, Mo.). 6-DMT and MP are reference compounds of the Research Laboratories of Kyowa Hakko Kogyo. Cl-DMATC (28) was purified from the NP6 culture as described by Dairi et al. (8).
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
Properties of MP production by S. aureofaciens NRRL
3203.
It is generally accepted that in S. aureofaciens
production of tetracyclines lags behind cell growth and is reduced by
excess ammonia or inorganic phosphate in the culture medium (9,
14). We cultivated S. aureofaciens NRRL 3203 under
various conditions and compared MP production with 6-DCT production
(Fig. 1). Under normal conditions in PK2
medium, MP production started at the same time as 6-DCT production, and
the level of production increased during the exponential and stationary
phases (Fig. 1A). Production of both compounds decreased similarly in
response to NH4Cl addition (Fig. 1B). Similar decreases
were also observed in the presence of excess
K2HPO4 (Fig. 1C). These results showed that the
fundamental characteristics of MP production were very similar to the
fundamental characteristics of 6-DCT production, suggesting that MP
production is related to 6-DCT production in S. aureofaciens.
|
Requirement for MP production in tetracycline antibiotic producers. Six tetracycline antibiotic producers were inoculated into PK2 medium and examined to determine whether pigment and tetracyclines were produced. As shown in Table 1, MP was produced not only in cultures of the 6-DCT producer NRRL 3203 but also in cultures of the 6-DMT producer S. aureofaciens H-8979 and Streptomyces psammoticus ATCC 14125. In contrast, no dark pigment was produced by the CTC producer S. aureofaciens NRRL 2209 or by the TC producer Streptomyces avellaneus ATCC 23730. These results suggested that MP production is dependent on a defect in the 6-methylation step but is independent of the 7-chlorination step. To investigate the correlation between MP production and a defect in the 6-methylation step, we derived CTC-producing recombinants from 6-DCT-producing mutants by replacing the defective genes for the 6-methylation reaction with functional genes from NRRL 2209.
Construction of CTC-producing gene replacement
recombinants and verification of the influence of the defect
in the 6-methylation reaction on MP production.
Genes for the
6-methylation reaction are located in a 32-kb region of the
S. aureofaciens chromosome (25). To
obtain the CTC-biosynthetic gene cluster, including functional genes
for the 6-methylation reaction, we constructed a cosmid library of the
chromosome of NRRL 2209 and isolated cosmid pGLA144 (37-kb insert) by
colony hybridization as described previously (8). A physical
map of cosmid pGLA144 is shown in Fig. 2.
|
Mutation analysis of the correlation between the 6-DCT-biosynthetic
pathway and MP production.
To further examine the possibility that
MP may be synthesized via the 6-DCT-biosynthetic pathway, we isolated
mutants that did not produce 6-DCT from cultures of the 6-DCT producer
H-7591 by selecting for cosynthesis (22) and by performing
genetic complementation experiments with integrative plasmids
containing either BamHI-digested or KpnI-digested
fragments of cosmid pGLA2 (Fig. 2). The mutants selected could be
divided into three classes based on their metabolites. Characteristics
of representative mutants are summarized in Table
2. Class Ia mutant NP41, which produced
neither MP nor 6-DCT but accumulated the penultimate intermediate
Cl-DMATC of the 6-DCT-biosynthetic pathway was a mutant that was
defective in anhydrotetracycline (ATC) oxygenase (1), the
enzyme that catalyzes the penultimate step in the 6-DCT-biosynthetic
pathway. The altered production properties of NP41 were simultaneously
restored by single-crossover integration of pKN108 DNA containing the
ATC oxygenase gene (tcsC; previously designated
chl-ORF2), which is located in the 1.8-kb SacI
segment (Fig. 2) (8). Two other ATC oxygenase-deficient
mutants had the same phenotype as NP41 (data not shown). Class Ib
mutant NP104 was a colorless mutant which did not produce MP or any
6-DCT-related compound but still could convert Cl-DMATC into 6-DCT,
which suggested that an early step in the 6-DCT-biosynthetic pathway
was blocked in this mutant. 6-DCT production and MP production were
simultaneously restored by single-crossover integration of pKN4 DNA
containing the minimal CTC polyketide synthase genes into the
chromosome. Similar results were obtained with two other class Ib
mutants (data not shown). In contrast, class II mutant NP733 was able to produce MP. The ability of this strain to produce 6-DCT, accompanied by a decrease in MP production, was restored by single-crossover integration of pKN2 DNA containing the 7-kb
KpnI-BamHI fragment of the 6-DCT biosynthesis
gene cluster into the chromosome. Another class II mutant, NP71,
produced similar results (data not shown). These results indicate that
some of the 6-DCT-biosynthetic enzymes, including ATC oxygenase, are
essential for MP production, and they strongly support the hypothesis
that MP is formed from a certain intermediate in the 6-DCT-biosynthetic
pathway.
|
Branch point in the 6-DCT-biosynthetic pathway. The simplest interpretation of the finding that ATC oxygenase is indispensable for MP production is that class II mutants lack the final step of the 6-DCT-biosynthetic pathway and the last intermediate of the pathway is the branch point that leads to MP and 6-DCT. However, the results of the following experiments contradict this interpretation. As shown in Table 2, class II mutant NP733, as well as class Ib mutant NP104, could convert Cl-DMATC into 6-DCT, while class Ia mutant NP41 could not convert Cl-DMATC into 6-DCT. Similar results were obtained when we performed cosynthesis tests with NP41 as the secretor strain. Another class II mutant, NP71, could also convert Cl-DMATC into 6-DCT (data not shown). These results indicated that class II mutants were defective in some step before Cl-DMATC in the 6-DCT-biosynthetic pathway, not in the final step. This implies that an intermediate before Cl-DMATC is the branch point and that after this point the ATC oxygenase reaction is involved in MP formation.
Although the putative branch point has not been investigated in detail, the branch point seems to be a step before the 7-chlorination step because the results indicated that cosynthesis by NP733 and 7-chlorination-deficient class Ia mutants produced 6-DMT but not 6-DCT without affecting the 7-chlorination activity of NP733 (data not shown). This suggested that NP733 has a defect before the 7-chlorination step. We did not investigate what caused the high molecular mass of MP. However, it seems that no enzymatic reaction participates in the change because there is no 6-DCT-producing variant that does not produce MP. In our preliminary experiments with five ATC oxygenase-attenuated mutants isolated from strain H-7591, production of 6-DCT and production of MP decreased, and there was a concomitant increase in production of Cl-DMATC, while the ratio of MP to 6-DCT increased (data not shown). These results suggest that ATC oxygenase activity affects the metabolic distribution between MP synthesis and 6-DCT synthesis. Based on this finding, ATC oxygenase might be responsible for redirecting an intermediate from the 6-DCT-biosynthetic pathway to MP synthesis in addition to its original function as the enzyme which catalyzes the penultimate step in 6-DCT biosynthesis. A pathway leading to synthesis of MP in S. aureofaciens is shown in Fig. 3.
|
| |
ACKNOWLEDGMENTS |
|---|
We thank Michiko Nakagawa and Erika Shimoda for excellent technical assistance. We are grateful to Youich Shinmasu for kindly providing a reference MP compound.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Technical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., 1-1 Kyowa-cho, Hofu, Yamaguchi 747-8522, Japan. Phone: 81 835 22 2518. Fax: 81 835 22 2466. E-mail: t.nakano{at}kyowa.co.jp.
Present address: Technical Research Laboratories, Kyowa Hakko Kogyo
Co., Ltd., Hofu, Yamaguchi 747-8522, Japan.
Present address: Division of Life Science, Graduate School of
Agricultural Science, Tohoku University, Sendai 981-8555, Japan.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
B hal, V.,
Z. Ho![]() álek, and Z. Van k.
1979.
Anhydrotetracycline oxygenase activity and biosynthesis of tetracyclines in Streptomyces aureofaciens.
Biotechnol. Lett.
1:177-182[CrossRef].
|
| 2. |
B hal, V., and I. S. Hunter.
1995.
Tetracyclines, p. 359-384.
In
L. C. Vining, and C. Stuttard (ed.), Genetics and biochemistry of antibiotics production. Butterworth-Heinemann, Newton, Mass.
|
| 3. | Bérdy, J., J. K. Pauncz, Z. M. Vajna, G. Horváth, J. Gyimesi, and I. Koczka. 1977. Metabolites of gentamicin-producing Micromonospora species. I. Isolation and identification of metabolites. J. Antibiot. 30:945-954[Medline]. |
| 4. |
Blumauerová, M.,
M. Mracek,
J. Vandrá ková,
M. Podojil,
Z. Ho![]() álek, and Z. Van k.
1969.
Regulation of biosynthesis of secondary metabolites. IX. The biosynthetic activity of blocked mutants of Streptomyces aureofaciens.
Folia Microbiol.
14:215-225.
|
| 5. | Bu'lock, J. D. 1965. The biosynthesis of natural products. McGraw-Hill Publishing Co. Ltd., London, United Kingdom. |
| 6. |
Bystrykh, L. V.,
M. A. Fernández-Moreno,
J. K. Herrema,
F. Malpartida,
D. A. Hopwood, and L. Dijkhuizen.
1996.
Production of actinorhodin-related "blue pigments" by Streptomyces coelicolor A3(2).
J. Bacteriol.
178:2238-2244 |
| 7. | Dairi, T., K. Aisaka, R. Katsumata, and M. Hasegawa. 1995. A self-defense gene homologous to tetracycline effluxing gene essential for antibiotic production in Streptomyces aureofaciens. Biosci. Biotechnol. Biochem. 59:1835-1841[Medline]. |
| 8. | Dairi, T., T. Nakano, K. Aisaka, R. Katsumata, and M. Hasegawa. 1995. Cloning and nucleotide sequence of the gene responsible for chlorination of tetracycline. Biosci. Biotechnol. Biochem. 59:1099-1106[Medline]. |
| 9. | DiMarco, A., and P. Pennella. 1959. The fermentation of the tetracyclines, p. 45-92. In D. J. D. Hockenhull (ed.), Progress in industrial microbiology. Heywood Press, London, United Kingdom. |
| 10. | Dubois, M., K. A. Gilles, J. K. Hamilton, P. A. Rebers, and F. Smith. 1956. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28:350-356[CrossRef]. |
| 11. | Hohn, B., and J. Collins. 1980. A small cosmid for efficient cloning of large DNA fragments. Gene 11:291-298[CrossRef][Medline]. |
| 12. | Honda, S., Y. Takekoshi, Y. Nakano, and Y. Arai. 1993. Bio-melanin. J. Soc. Cosmet. Chem. Japan 27:432-440. |
| 13. | Hopwood, D. A., M. J. Bibb, K. F. Chater, T. Kieser, C. J. Bruton, H. M. Kieser, D. J. Lydiate, C. P. Smith, J. M. Ward, and H. Schrempf. 1985. Genetic manipulation of Streptomyces: a laboratory mannual. The John Innes Foundation, Norwich, England. |
| 14. |
Ho![]() álek, Z.,
M. Blumauerová, and Z. Van k.
1979.
Tetracycline antibiotics, p. 293-354.
In
A. H. Rose (ed.), Economic microbiology. Academic Press, London, United Kingdom.
|
| 15. | Kase, H., Y. Odakura, and K. Nakayama. 1982. Sagamicin and the related aminoglycoside: fermentation and biosynthesis. I. Biosynthetic studies with the blocked mutants of Micromonospora sagamiensis. J. Antibiot. 35:1-9[Medline]. |
| 16. |
Kormanec, J.,
B. e uchová, and M. Farka ovský.
1993.
Optimization of Streptomyces aureofaciens transformation and disruption of the hrdA gene encoding a homologue of the principal sigma factor.
J. Gen. Microbiol.
139:2525-2529.
|
| 17. | Leenheer, A. P. D., and H. J. C. F. Nelis. 1977. Reversed-phase high-performance liquid chromatography of doxycycline. J. Chromatogr. 140:293-299[CrossRef][Medline]. |
| 18. | Locci, L. 1989. Streptomycetes and related genera, p. 2451-2508. In S. T. Williams, M. E. Sharpe, and J. G. Holt (ed.), Bergey's manual of systematic bacteriology, vol. 4. Williams & Wilkins, London, United Kingdom. |
| 19. | Maniatis, T., E. F. Fritsch, and J. Sambrook. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 20. |
McCormick, J. R. D.
1965.
Biosynthesis of the tetracyclines, p. 73-91.
In
Z. Van k, and Z. Ho![]() álek (ed.), Biogenesis of antibiotic substances. The Czechoslovak Academy of Science, Praque, Czechoslovakia.
|
| 21. | McCormick, J. R. D. April 1971. 6-Demethylchlortetracyclines and method for preparing the same. U.S. patent 3,616,239. |
| 22. | McCormick, J. R. D., U. Hirsch, N. O. Sjolander, and A. P. Doerschuk. 1960. Cosynthesis of tetracyclines by pairs of Streptomyces aureofaciens mutants. J. Am. Chem. Soc. 82:5006-5007[CrossRef]. |
| 23. | Omura, S., and Y. Tanaka. 1984. Biochemistry, regulation, and genetics of macrolide production, p. 199-229. In S. Omura (ed.), Macrolide antibiotics. Academic Press, New York, N.Y. |
| 24. | Rhodes, P. M., N. Winskill, E. J. Friend, and M. Warren. 1981. Biochemical and genetic characterization of Streptomyces rimosus mutants impaired in oxytetracycline biosynthesis. J. Gen. Microbiol. 124:329-338. |
| 25. | Ryan, M. J., J. A. Lotvin, N. Strathy, and S. E. Fantini. December 1996. Cloning of the biosynthetic pathway for chlortetracycline and tetracycline formation and cosmids useful therein. U.S. patent 5,589,385. |
| 25a. | Tomita, K. July 1996. Japanese patent. |
| 26. |
Van k, Z.,
J. Cudlin,
M. Blumauerová, and Z. Ho![]() álek.
1971.
How many genes are required for the synthesis of chlortetracycline?
Folia Microbiol.
16:225-240.
|
| 27. | Virgilio, A., and C. Hengeller. December 1962. Process for the manufacturer of 6-demethylchlortetracycline. U.S. patent 3,070,514. |
| 28. | Webb, J. S., R. W. Broschard, D. B. Cosulich, W. J. Stein, and C. F. Wolf. 1957. Demethyltetracyclines. Structure studies. J. Am. Chem. Soc. 79:4563-4564. |
| 29. | Yanisch-Perron, C., J. Viera, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33:103-119[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Microbiol. Mol. Biol. Rev. | Eukaryot. Cell | All ASM Journals |
|---|